The Food & Drug Administration (FDA) has approved a new treatment for the respiratory condition called Chronic Obstructive Pulmonary Disease (COPD).
According to the FDA, patients who suffer from this often deadly ailment now have a new tool with which to treat symptoms. The medication is delivered via inhaler, with a spray called Striverdi Respimat and the active ingredient known as olodaterol. It is believed that the drug works by relaxing the airway muscles in the lungs. The drug is often prescribed to be taken once a day, and can be used over a prolonged period of time.
The FDA has conducted testing of the medication, including comparison with a placebo. More than 3,000 people with a diagnosis of COPD were included in the study. Those who used the inhaler were compared to a control group that took a placebo. The researchers found that those who were on the medication exhibited improved lung function compared to those who were on the placebo